Unknown

Dataset Information

0

BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies.


ABSTRACT: BCL-2 overexpression has been associated with resistance to chemotherapy and reduced survival in acute myeloid leukemia (AML), but few data are available in elderly patients, a subset accounting for majority of AML cases and with dismal prognosis. We retrospectively analyzed 113 AML patients aged ≥65 years treated with 3 + 7 chemotherapy (n = 51) or hypomethylating agents (HMAs) (n = 62), evaluating the role of BCL-2 expression on complete remission (CR) and overall survival (OS). BCL-2 was expressed in 81 patients (72%), more frequently in those with unfavorable cytogenetic-molecular risk. CR was achieved in 34.5% cases, without differences according to BCL-2 expression or induction therapy. In the whole population 1-year OS was 39%, similar in BCL-2+ and BCL-2- cases. In BCL-2 positive patients OS was superior with HMAs (56% vs. 25% with 3 + 7; p = 0.02), while no advantage for HMA was found in BCL-2 negative cases (36% vs. 27% for 3 + 7). Therapy with HMAs was the only factor associated with longer OS in BCL-2+ AML by multivariable analysis. Use of HMAs, possibly in combination with BCL-2 inhibitors, appears to be particularly appealing in BCL2+ AML, where it is associated with superior survival.

SUBMITTER: Tiribelli M 

PROVIDER: S-EPMC8585096 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies.

Tiribelli Mario M   Michelutti Angela A   Cavallin Margherita M   Di Giusto Sara S   Simeone Erica E   Fanin Renato R   Damiani Daniela D  

Journal of clinical medicine 20211030 21


BCL-2 overexpression has been associated with resistance to chemotherapy and reduced survival in acute myeloid leukemia (AML), but few data are available in elderly patients, a subset accounting for majority of AML cases and with dismal prognosis. We retrospectively analyzed 113 AML patients aged ≥65 years treated with 3 + 7 chemotherapy (<i>n</i> = 51) or hypomethylating agents (HMAs) (<i>n</i> = 62), evaluating the role of BCL-2 expression on complete remission (CR) and overall survival (OS).  ...[more]

Similar Datasets

| S-EPMC10892390 | biostudies-literature
| S-EPMC11337186 | biostudies-literature
| S-EPMC9143805 | biostudies-literature
| S-EPMC9977880 | biostudies-literature
| S-EPMC8469271 | biostudies-literature
| S-EPMC5802565 | biostudies-literature
| S-EPMC7764821 | biostudies-literature
| S-EPMC10741742 | biostudies-literature
| S-EPMC6906689 | biostudies-literature
| S-EPMC8800915 | biostudies-literature